LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Apellis Pharmaceuticals Inc

Closed

SectorHealthcare

17.45 -5.42

Overview

Share price change

24h

Current

Min

17.16

Max

18.52

Key metrics

By Trading Economics

Income

-56M

-92M

Sales

-46M

167M

EPS

-0.74

Profit margin

-55.292

Employees

705

EBITDA

-56M

-80M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+112.22% upside

Dividends

By Dow Jones

Next Earnings

31 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-336M

2.2B

Previous open

22.87

Previous close

17.45

News Sentiment

By Acuity

18%

82%

28 / 382 Healthcare

Apellis Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

21 May 2025, 23:25 UTC

Hot Stocks

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 May 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 May 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Operations in Uruguay

21 May 2025, 21:01 UTC

Major Market Movers

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 May 2025, 20:51 UTC

Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21 May 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 May 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 May 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 May 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 May 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 May 2025, 23:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 May 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 May 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 May 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 May 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 May 2025, 23:28 UTC

Earnings

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 May 2025, 23:27 UTC

Earnings

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 May 2025, 23:26 UTC

Earnings

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 May 2025, 23:26 UTC

Earnings

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 May 2025, 23:26 UTC

Earnings

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 May 2025, 23:23 UTC

Acquisitions, Mergers, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 May 2025, 23:22 UTC

Acquisitions, Mergers, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 May 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 May 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 May 2025, 21:42 UTC

Top News
Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 May 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Ops in Uruguay

21 May 2025, 21:07 UTC

Top News

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 May 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21 May 2025, 20:59 UTC

Top News

Walmart to Cut 1,500 Jobs -- WSJ

21 May 2025, 20:52 UTC

Earnings

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Peer Comparison

Price change

Apellis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

112.22% upside

12 Months Forecast

Average 37.5 USD  112.22%

High 60 USD

Low 18 USD

Based on 21 Wall Street analysts offering 12 month price targets forApellis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

21 ratings

13

Buy

8

Hold

0

Sell

Sentiment

By Acuity

28 / 382 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.